Yahoo
HKSE - Delayed Quote HKD

Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK)

99.850 -13.150 (-11.64%)
At close: November 6 at 4:08:50 PM GMT+8
Chart Range Bar
Loading chart for 2526.HK
  • Previous Close 113.000
  • Open 129.200
  • Bid 99.450 x --
  • Ask 100.500 x --
  • Day's Range 95.150 - 129.200
  • 52 Week Range 95.150 - 765.500
  • Volume 378,650
  • Avg. Volume 105,712
  • Market Cap (intraday) 8.875B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.560
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 294.77
  • Moby Rating Neutral

Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments. The company's products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which enables automated scanning, positioning, image acquisition, and output of chromosome or cell samples for a range of cytogenetics applications, including genetics health, radiation health, and hemato-oncology; and KayoFlow automatic cell harvester for pre-analytical processing of various sample types, including peripheral blood, amniotic fluid, and bone marrow. It also offers KayoFlow integrated slide preparation and staining system for pre-analytical slide preparation and staining of chromosome samples; KayoFlow workflow integration systems; and laboratory reagents and consumables. In addition, the company provides integrated storage, computation, training, and inference localized solutions; and iMed MaaS medical imaging AI platform, a cloud-based service platform. Hangzhou Diagens Biotechnology Co., Ltd. was founded in 2016 and is headquartered in Hangzhou, China.

www.diagens.com

174

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2526.HK
54.41%
HANG SENG INDEX (^HSI)
4.48%

1-Year Return

2526.HK
54.41%
HANG SENG INDEX (^HSI)
7.57%

3-Year Return

2526.HK
54.41%
HANG SENG INDEX (^HSI)
36.26%

5-Year Return

2526.HK
54.41%
HANG SENG INDEX (^HSI)
1.56%

Analyst Insights

View More

Analyst Price Targets

294.77
294.77 Average
99.850 Current
294.77 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -66.38%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    183.31M

  • Net Income Avi to Common (ttm)

    -121.68M

  • Diluted EPS (ttm)

    -1.560

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    654.59M

  • Total Debt/Equity (mrq)

    7.19%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: